- Home
- ADAG vs PLX Comparison
ADAG vs PLX Comparison
Compare ADAG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- PLX
- Stock Information
- Founded
- ADAG 2011
- PLX 1993
- Country
- ADAG China
- PLX Israel
- Employees
- ADAG N/A
- PLX N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADAG Health Care
- PLX Health Care
- Exchange
- ADAG Nasdaq
- PLX Nasdaq
- Market Cap
- ADAG 95.6M
- PLX 79.4M
- IPO Year
- ADAG 2021
- PLX 1998
- Fundamental
- Price
- ADAG $2.14
- PLX $1.39
- Analyst Decision
- ADAG Strong Buy
- PLX
- Analyst Count
- ADAG 1
- PLX 0
- Target Price
- ADAG $5.00
- PLX N/A
- AVG Volume (30 Days)
- ADAG 73.9K
- PLX 310.7K
- Earning Date
- ADAG 07-25-2024
- PLX 11-14-2024
- Dividend Yield
- ADAG N/A
- PLX N/A
- EPS Growth
- ADAG N/A
- PLX N/A
- EPS
- ADAG N/A
- PLX N/A
- Revenue
- ADAG $815,746.00
- PLX $45,667,000.00
- Revenue This Year
- ADAG N/A
- PLX N/A
- Revenue Next Year
- ADAG $2.70
- PLX $88.94
- P/E Ratio
- ADAG N/A
- PLX N/A
- Revenue Growth
- ADAG N/A
- PLX N/A
- 52 Week Low
- ADAG $1.34
- PLX $0.82
- 52 Week High
- ADAG $4.38
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- ADAG 37.47
- PLX 66.10
- Support Level
- ADAG $2.20
- PLX $1.14
- Resistance Level
- ADAG $3.14
- PLX $1.34
- Average True Range (ATR)
- ADAG 0.30
- PLX 0.07
- MACD
- ADAG -0.09
- PLX 0.02
- Stochastic Oscillator
- ADAG 18.63
- PLX 92.59
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.